Collagen, Bone Wax or Compression for Cancellous Bone Bleeding After Single-Ray Amputation
NCT: NCT07788846 · NOT_YET_RECRUITING
Brief Summary
This is a prospective, three-arm, parallel-group randomized controlled clinical trial evaluating fibrillar Type-I collagen haemostat, conventional bone wax, and standardized compression alone for control of bleeding from exposed cancellous bone following single-ray amputation. Adults undergoing single-ray amputation involving the phalanx, metacarpal or metatarsal will be randomized in a 1:1:1 ratio. The primary outcome is complete haemostasis of the exposed cancellous bone surface following the prespecified intervention and anatomical-level-specific standardized compression period, without rescue haemostatic intervention during the subsequent standardized 60-second observation period. Secondary outcomes include time to haemostasis, haemostasis grade, rescue haemostasis, blood loss, rebleeding, surgeon-rated ease of application, intervention handling time, postoperative bleeding and wound outcomes.
Frequently Asked Questions
What is Collagen, Bone Wax or Compression for Cancellous Bone Bleeding After Single-Ray Amputation?
Collagen, Bone Wax or Compression for Cancellous Bone Bleeding After Single-Ray Amputation is a clinical trial registered under NCT07788846. Current status: NOT_YET_RECRUITING.
What is the status of NCT07788846?
The current status of NCT07788846 (Collagen, Bone Wax or Compression for Cancellous Bone Bleeding After Single-Ray Amputation) is: NOT_YET_RECRUITING.
When did Collagen, Bone Wax or Compression for Cancellous Bone Bleeding After Single-Ray Amputation start?
Collagen, Bone Wax or Compression for Cancellous Bone Bleeding After Single-Ray Amputation started on 2026-08.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.